Statera Biopharma (STAB) 10-Q2012 Q1 Quarterly report

Filed: 7 May 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: allied, Antimycon, apparent, approach, Arkil, ASU, back, backlog, behalf, Certification, combat, combating, commonly, compensatory, counteract, cumulative, decline, discontinued, dual, duly, energy, expanded, experienced, fact, formatted, hereto, iv, Kogan, long, Mobilan, negligible, neil, nonproprietary, OOO, opposed, Oxley, prominence, pursue, pursued, pursuing, radio, readily, Revercom, seeking, Skolkovo, tagged, text, thereunto, Topic, traditional, travel, undersigned, unfunded, unrestricted, usage, vi, XBRL, Yakov

Removed: accident, accredited, achieved, achievement, acquired, activation, adverse, adversely, aggressive, amortization, amounted, anticancer, antitumor, apoptotic, application, area, attack, attributed, Authority, biodefense, Biologic, biology, Biomedical, broad, carcinoma, case, cell, cerebral, certainty, characteristic, chemotherapy, collaboration, collateral, colon, commercialize, concept, connection, consulting, continuing, Conversely, damage, death, defective, deficit, delayed, demonstrate, demonstrated, depend, depending, depreciation, derivative, design, destroy, determinant, develop, devoted, disease, dosage, effectively, efficacy, enable, enter, established, event, exclusive, exercisable, exhaust, exist, experimental, expiration, explained, exploring, expression, extent, external, failure, fast, fatal, favorable, focused, formal, found, foundation, geared, healthy, heart, high, higher, host, identification, identifying, IIa, immune, important, individual, induced, ineffective, inherent, initial, innate, interaction, introduce, investigation, investigational, ischemia, issuable, joint, kidney, kill, large, largely, larger, license, licensing, listed, liver, mammalian, manipulated, manufacturing, marketing, mechanism, mediated, meet, mentioned, microflora, military, modified, modulation, mouse, NASDAQ, natural, naturally, obtained, offering, operating, order, organ, partner, patient, pharmaceutical, Phase, placement, planned, predict, primary, programmed, project, proportion, proposed, prospective, prostate, protect, protectan, protecting, protection, protective, rapid, rat, RCC, recently, receptor, recurrence, reduced, reducing, regimen, regression, regulated, regulatory, renal, residing, resistance, response, resulted, resulting, reveal, reversibly, safety, sarcoma, scientific, scope, screening, service, shed, simultaneously, site, small, source, specific, spectrum, spend, stroke, subsequent, substantial, successfully, suggest, suggesting, supporting, suppressed, sustained, symbol, system, target, targeting, technological, temporarily, terminated, terrorist, test, testing, therapeutic, tightly, tissue, track, transplanted, treatment, tumor, twelve, ultimately, unsafe, variability, venture, wide, withdraw

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

STAB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification*

In connection with the Quarterly Report of Cleveland BioLabs, Inc., (the “Company”), on Form 10-Q for the quarter ending March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Periodic Report”) pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.§ 1350), Yakov Kogan, Interim Chief Executive Officer of the Company, and C. Neil Lyons, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1. The Periodic Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Periodic Report.

Dated: May 7, 2012	By:	/s/ YAKOV KOGAN
		Yakov Kogan
		Interim Chief Executive Officer
		(Principal Executive Officer)


Dated: May 7, 2012	By:	/s/ C. NEIL LYONS
		C. Neil Lyons
		Chief Financial Officer
		(Principal Financial Officer)

This certification accompanies the Periodic Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cleveland BioLabs, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Periodic Report), irrespective of any general incorporation language contained in such filing.